DOCSLIB.ORG

Lifesciences 2020 – Innovation in Motion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lifesciences 2020 – Innovation in Motion BIV LIFESCIENCES 2020 OFFICIAL PUBLICATION SPONSOR PUBLISHED BY Get ahead of the pack. Social • Google • Websites • Programmatic Glacier Media Digital experts help businesses succeed online. Contact us for a FREE Digital Audit [email protected] US-CHINA PHASE ONE TRADE DEAL: CHINA’S IP COMMITMENTS TO THE LIFE SCIENCES INDUSTRY Written by Jayde Wood & Jennifer Marles A STRONGER INTELLECTUAL pharmaceutical patent applicants to secure agreements will be to move Canada and PROPERTY REGIME IN THE MAKING patent protection in China. China closer in this area. On 15 January 2020, China and the US China will also be required to establish an OPPORTUNITIES FOR LIFE SCIENCES signed an agreement on a Phase One trade effective mechanism for early resolution of COMPANIES deal, which could significantly improve patent disputes, which includes a system the ability of life sciences companies to provide notice to a patent holder that a China’s IP commitments under this to protect their intellectual property in generic drug company is seeking approval Agreement will likely create new China. The first chapter of the Agreement of a version of its patented drug. Such a opportunities for life sciences companies addresses inadequacies in China’s IP regime would be similar in concept to the wishing to market their innovative products regime. The Agreement states that China Patented Medicines (Notice of Compliance) in China, the world’s second-largest life recognizes the importance of IP protection regime that exists in Canada. sciences market. Companies should closely and believes that enhancing IP protection watch the developments of China’s IP and enforcement will boost innovation, PATENT TERM ADJUSTMENT AND regime so that they can assess the potential grow innovation-driven enterprises, and EXTENSION impact on their business and patenting promote high quality economic growth. strategies. Some specific IP concerns addressed by China agrees to provide (i) patent the Agreement are pharmaceutical-related term adjustment to compensate for As intellectual property lawyers, we intellectual property and patent term unreasonable delays that occur in granting help life sciences companies define and adjustment and extension. a patent and (ii) patent term extension protect their innovations. We also help our to compensate for unreasonable delays clients to seize opportunities arising from MORE PHARMACEUTICAL PATENT during pharmaceutical product marketing changing IP regimes. If you have questions RIGHTS approvals. Patent term adjustment and about securing your intellectual property extension are particularly important for in Canada, China or other markets, we can China agrees to provide “effective pharmaceutical patents because it often help. protection and enforcement of takes a long time to bring a drug to market. pharmaceutical-related intellectual property rights, including patents and Patent term adjustment is not available undisclosed test or other data submitted as in Canada but patent term extension a condition of marketing approval”. of up to two years has been available since 2017 for patents pertaining to new China will be required to permit medicinal ingredients or new combinations pharmaceutical patent applicants to rely on of medicinal ingredients for human or supplemental data to satisfy patentability veterinary use. Canada will also have to requirements, including sufficiency of add provisions relating to patent term disclosure and inventiveness. This change adjustment to account for delays in the will bring China in line with practices examination of patent applications to Jayde Wood, Associate Jennifer Marles, Partner in other countries such as the US and comply with its obligations under the Intellectual Property Intellectual Property Europe, although such data is not currently Canada-US-Mexico Agreement (CUSMA). Lawyer Lawyer admissible in Canada. This may help So the effect of these international From research to market, we provide intellectual property support for leaders in life sciences. patentable.com Oyen Wiggs Green & Mutala LLP BIV 4 | LIFESCIENCES 2020 PUBLISHED BY BUSINESS IN VANCOUVER CONTENTS BIV LIFESCIENCES 2020 OFFICIAL PUBLICATION SPONSOR PUBLISHED BY PRESIDENT: Alvin Brouwer PUBLISHER AND EDITOR-IN-CHIEF, BUSINESS IN VANCOUVER; VICE-PRESIDENT, GLACIER MEDIA: Kirk LaPointe LIFESCIENCES BC MANAGING EDITOR: Susan Ogilvie EDITOR: Meg Yamamoto DESIGN: Petra Kaksonen PRODUCTION: Rob Benac CONTRIBUTORS: Marke Andrews, Nelson Bennett, Chuck Chiang, Jennifer Hamilton, Glen Korstrom, Dene Moore, Tyler Orton, Brigitte Petersen, Albert Van Santvoort RESEARCHERS: Anna Liczmanska, Arthur Xie 24 DIRECTOR, SALES AND MARKETING: Pia Huynh SALES MANAGER: Laura Torrance FEATURES ADVERTISING SALES: Blair Johnston, Corinne Tkachuk, Chris Wilson, Betty 9B.C.’S LIFE SCIENCE ASSETS Jin, Margaret Garrison ADMINISTRATOR: Katherine Butler Seven key organizations in the sector LifeSciences is published by BIV 22 24FROM LAB TO PHARMACY Magazines, a division of BIV Media Group, 303 Fifth Avenue West, B.C. biotechs find niches, shortcuts Vancouver, B.C. V5Y 1J6, 26IMAGING INGENUITY 604-688-2398, fax 604-688-1963, biv.com. Game-changing innovations in radiology Copyright 2020 Business in 28INNOVATING FOR HEALTH Vancouver Magazines. All rights reserved. No part of this book Health authorities get creative may be reproduced in any form or incorporated into any information 32DATA IS POWER retrieval system without permission Access to health data improves outcomes of BIV Magazines. The publishers are not responsible in whole or in part 36FABCOUVER for any errors or omissions in this publication. Therapeutic antibody sector one to watch ISSN 1205-5662 Publications Mail Agreement No.: 40069240. Registration No.: 8876. Return undeliverable Canadian Message from Canada’s Minister of addresses to Circulation Department: Innovation, Science and Industry 5 303 Fifth Avenue West, Vancouver, B.C. V5Y 1J6 Message from the Minister of Email: [email protected] Jobs, Economic Development and Cover: Tim Gottschick/Bay6 Competitiveness 6 Creative Inc. Message from the president and CEO 7 SPONSOR Biggest life sciences 26 companies in B.C. 34 2019 clinical milestones in B.C.’s life sciences sector 38 2019 investments in B.C.’s PRODUCED BY life sciences sector 39 Life sciences companies at a glance 40 LifeSciences BC membership directory 42 22nd annual LifeSciences BC award winners 45 BIV | 5 MESSAGE FROM CANADA’S MINISTER OF INNOVATION, SCIENCE AND INDUSTRY NAVDEEP BAINS, CANADA’S MINISTER OF We also understand that our government’s policy and funding INNOVATION, SCIENCE AND INDUSTRY programs must help spur private-sector innovation. As part of our Innovation Superclusters Initiative, our Digital Technology We believe that strong science makes Supercluster, based in British Columbia, is bringing together for a strong Canada; and when it companies and researchers to collaborate on generating innov- comes to Canada’s life science sec- ations in areas where Canada can lead globally. For example, tor, British Columbia is a true leader. using bigger, better data sets and cutting-edge applications This province has an internationally of augmented reality, cloud computing and machine learning acknowledged and respected base of to improve service delivery in precision health, among other expertise that we are proud to sup- areas. Over the next 10 years, our supercluster investments port and partner with. Recently, our are expected to help create thousands of middle-class jobs and government announced a big round establish British Columbia as a 21st-century global leader in life of investments in genomics and stem science innovations. cell research; no surprise that large portions of that funding will In all this, our government is fortunate to be guided by the rec- be dedicated to the important work going on at many of British ommendations of our health and bioscience Economic Strategy Columbia’s world-class research institutions. Table experts. This blue-ribbon panel, lead by Quark Venture’s To stimulate innovation, our government must also play the Karimah Es Sabar, leverages insights from industry leaders to role of regulator in the life sciences, such as Health Canada’s support transformative growth in the sector. I am pleased to Regulatory Review of Drugs and Devices. This process allows our report that we are implementing a major portion of the group’s government to review information on new drugs and devices for recommendations with more work to follow. priority diseases quickly, so that Canadians have faster access to None of this would be possible without the steadfast support of new and innovative treatments. To build on this, we are working organizations like yours. On behalf of the Government of Canada, to develop regulatory road maps for many of our high-potential I would like to thank LifeSciences BC and your members for all sectors – including health. We want to make regulatory systems you do to keep British Columbia’s life science sector world-class. more agile, transparent and responsive, with a focus on sup- Together, we are advancing a strong life science sector in B.C., porting innovation and business investment. making for a healthier and more prosperous country. É NEW Bachelor of Pharmaceutical Sciences Program UBC’s Faculty of Pharmaceutical Sciences is delighted to announce the new Bachelor of Pharmaceutical Sciences Program. This exciting new degree program will harness our world class research and educational environment to prepare graduates for careers in
Load more

Recommended publications
  • Investment in Early Translational Cancer Research in Canada, 2005–2007
    Investment in early Translational Cancer research, 2005–2007 a SPeCIaL rePOrT FrOM THe CaNaDIaN CaNCer reSearCH aLLIaNCe’S SurVey OF GOVerNMeNT aND VOLuNTary SeCTOr INVeSTMeNT IN CaNCer reSearCH February 2011 For additional copies of this publication, please contact: Canadian Cancer Research Alliance (CCRA) 1 University Avenue, Suite 300 Toronto, Ontario M5J 2P1 CANADA Tel.: (416) 915-9222, ext. 5739 Fax: (416) 915-9224 Email: [email protected] This publication is also available at the following address http://www.ccra-acrc.ca. It is formatted for two-sided printing. Permission To Reproduce Except as otherwise specifcally noted, the information in this publication may be reproduced, in part or in whole and by any means, without charge or further permission from the Canadian Cancer Research Alliance (CCRA), provided that due diligence is exercised in ensuring the accuracy of the information reproduced, CCRA is identifed as the source institution, and the reproduction is not represented as being an offcial version of the information, or as having been made in affliation with, or with the endorsement of, CCRA. Suggested Citation: Canadian Cancer Research Alliance (2010). Investment in Early Translational Cancer Research, 2005–2007: A Special Report from the Canadian Cancer Research Alliance’s Survey of Government and Voluntary Sector Investment in Cancer Research. Toronto: CCRA. © Canadian Cancer Research Alliance, 2011 ISBN 978-0-9866841-1-1 (print) / ISBN 978-0-9866841-0-4 (PDF) Aussi offert en français sous le titre : Investissements dans les étapes initiales de la recherche translationnelle sur le cancer, de 2005 à 2007 : un rapport spécial sur l’enquête de l’Alliance canadienne pour la recherche sur le cancer sur les investissements effectués dans la recherche sur le cancer par les organismes gouvernementaux et non gouvernementaux.
    [Show full text]
  • Journal of Family Practice Oncology
    Journal of Family Practice Oncology Issue Number 22, Spring 2014 | www.fpon.ca Insight into BC’s Colon Screening Program By Dr. Jennifer Telford, Medical Director, Registering eligible patients into the program Provincial Colon Screening Program ensures that the BC Cancer Agency receives FIT results and can refer patients with an Since November 15, 2013 the Colon abnormal FIT or those that are higher than Screening Program has been available average risk to one of 20 health authority across the province. Physicians can register patient coordinators for pre-colonoscopy asymptomatic patients ages 50 to 74 in the assessments. Colon Screening Program as follows: Abnormal FIT Results Colon Screening Program For average risk patients: Jennifer Telford MD MPH FRCPC February 20, 2014 FECAL IMMUNOCHEMICAL TEST (FIT) An abnormal FIT indicates that there www.screeningbc.ca/colon may be bleeding from somewhere in the • Select the ‘Fecal Occult Blood, age 50- colon or rectum. Blood can be present 74, asymptomatic q2y (copy to Colon in the stool for many different reasons, Watch Dr. Jennifer Telford’s hour long Screening Program)’ option on the including hemorrhoids, ulcers, anal fissures, Webcast on the BC’s new Provincial updated Standard Outpatient Laboratory diverticular disease, or inflammation. Colon Screening Program at www.fpon.ca Requisition. – CME Initiatives. • A copy of the FIT report will be sent to the Approximately 15% of individuals screened with Colon Screening Program at the BC Cancer FIT will have an abnormal FIT result and will Agency. require colonoscopy. Of those with an abnormal • For colorectal cancer screening in FIT, 4% will have cancer and approximately 60% individuals less than 50 years of age.
    [Show full text]
  • TRIUMF Team Welcomes Isotope Investment
    Canada’s national laboratory for particle and nuclear physics Laboratoire national canadien pour la recherche en physique nucléaire et en physique des particules News Release | For Immediate Release | February 28, 2013, 9:00 a.m. PST TRIUMF Team Welcomes Isotope Investment (Vancouver, BC) --- The CycloTech99 consortium welcomes the investment by Natural Resources Canada (NRCan) through the Isotope Technology Acceleration Program (ITAP) and our partners in provinces, universities, and industry. These funds represent a continued investment from NRCan resulting from our earlier efforts during the Non-reactor-based Isotope Supply Contribution Program (NISP). As announced in February 2012, CycloTech99 has demonstrated the capability to produce the world’s most popular medical isotope, technetium-99m, on medical cyclotrons already installed in Ontario and British Columbia. Our solution in ITAP includes regulatory approval and commercial roll out for a truly national technetium production solution for the benefit of all Canadians, by securing medical isotopes for our patients when the NRU reactor in Chalk River ceases production in 2016. We have a clear pathway to address and stabilize this gap. Principal investigator Paul Schaffer leads the team and is head of TRIUMF’s Nuclear Medicine Division. He said, “The federal government has invested in our team to deliver an innovation for the benefit of all Canadians. We look forward to delivering a domestic solution to the medical isotope crisis in the near future.” “The Harper Government is working to find new ways of producing medical isotopes for the diagnosis of heart disease and cancer in Canadians,” said the Honourable Joe Oliver, Canada’s Minister of Natural Resources.
    [Show full text]
  • Taking It Step by Step: a Guide for Women Diagnosed with Gynecological Cancer
    Taking it Step by Step A GUIDE FOR WOMEN DIAGNOSED WITH GYNECOLOGICAL CANCER With great thanks In This Guide Taking it Step by Step: A guide for women 1 Understanding Your Diagnosis _________ 3 diagnosed with gynecological cancer was envisioned and created by the BC/Yukon 2 Treatment Pathway & Timelines _______ 5 Women’s Cancer Information & Support Alliance. This group’s collaborative effort 3 Your Cancer Type _______________________6 includes: women with gynecological cancers; Uterine Cancer __________________________________6 the Canadian Cancer Society BC & Yukon; the Ovarian/Fallopian Tube Cancer ________________9 Gynecologic Tumour Group and Supportive Care Cervical Cancer ________________________________12 Professionals, BC Cancer Agency; Ovarian Cancer Vulvar Cancer __________________________________15 Canada Pacific Yukon Region and UBC School of Vaginal Cancer _________________________________17 Physical Therapy. The production and design for Taking it Step 4 Understanding Your Pathology Report _19 by Step was generously funded by the Cancer Program, Public Health Agency of Canada. The 5 Getting Ready _________________________20 views expressed herein do not represent the views of the Public Health Agency of Canada 6 Questions For Your Medical Team _____21 The printing and ongoing evaluation of Taking 7 Other Common Questions ____________22 it Step by Step is generously funded by the BC Cancer Foundation. The BC Cancer Foundation 8 Your Emotions __________________________23 is an independent charitable organization that raises
    [Show full text]
  • Breast Cancer Companion Guide
    Breast Cancer Companion Guide GENEROUSLY FUNDED BY Information Kit © BC Cancer Agency Revised 2013 1 Start Here Be Proactive What’s included in your Kit: 1 Start Here Being diagnosed with breast cancer can be frightening, confusing and overwhelming. You may have many questions • BREAST CANCER COMPANION GUIDE 2 Test Results & Appointments and concerns. This Breast Cancer Information Kit was created to help you, your family and friends during this difficult time. • INTELLIGENT PATIENT GUIDE TO 3 Coping & Support This Breast Cancer Companion Guide is the place to begin and BREAST CANCER will help you interact with the resources in this kit. Sections provides suggested readings, key questions to ask, and 4 Learn About Your Cancer • EXERCISES AFTER BREAST CANCER: additional resources for each step along the journey. A GUIDE FOR WOMEN Keep in mind, that every person with cancer is unique and your 5 Surgery need for information and support will differ from others. You • A NUTRITION GUIDE FOR WOMEN may not require some of the information included in this Kit, WITH BREAST CANCER 6 Adjuvant Therapies nor will you need to read it all at once. Simply take one step at a time. Ask questions, learn about your options, and trust what • ABREAST & THE REST NEWSLETTER 7 Reconstructive Surgery feels right to you. • AFTER BREAST CANCER TREATMENT: 8 Lifestyle The Breast Cancer Information Kit was developed WHAT NEXT? by persons who have experienced breast cancer and 9 Life After Breast Cancer professionals from the Alliance for Breast Cancer • A PARALLEL JOURNEY: MY PARTNER HAS Information & Support, BC Cancer Agency, Victoria Breast BREAST CANCER - HOW CAN I HELP? 10 BC Cancer Foundation Health Centre and the Canadian Cancer Society.
    [Show full text]
  • Department of Medicine 2009 Annual Report
    Department of Medicine 2009 Annual Report The University of British Columbia, Vancouver, Canada CONTENTS MESSAGE FROM DR. GRAYDON MENEILLY 2 Heads & Directors 4 Administration 5 Research 7 Committee for Appointments, Reappointments, Promotion and Tenure 8 Teaching Effectiveness Committee 10 DIVISION REPORTS AIDS 11 Allergy & Immunology 20 Cardiology 23 Community Internal Medicine 36 University of British Columbia Critical Care Medicine 39 Department of Medicine 2009 Annual Report Endocrinology 44 Gastroenterology 47 Graydon S. Meneilly General Internal Medicine 53 Professor and Eric W. Hamber Chair Geriatric Medicine 60 Head, Department of Medicine, Hematology 64 Vancouver Hospital Infectious Diseases 67 Contributors Medical Oncology 69 Division Heads and Administrators Program Directors and Managers Nephrology 71 Neurology 77 Linda Rasmussen Physical Medicine & Rehabilitation 85 Director of Administration Department of Medicine Respiratory Medicine 88 Rheumatology 91 Editor Donna Combs Members at Large 97 Department of Medicine EDUCATIONAL PROGRAMS Designer Clinical Investigator Program 98 Sabina Fitzsimmons Department of Medicine Continuing Medical Education Program 103 Graduate Studies Program in Experimental Medicine 104 Cover photo Courtesy of “Tourism Vancouver” Postgraduate Education Program 109 International Health Project 111 Photography Undergraduate Education Program 113 Janis Franklin Andy Fang Photospin Departmental Strategic Directions 2009 114 Canada Research Chairs & Endowed Chairs 121 Printer RR Donnelly Research Funding 128 Publications 129 Affiliated Institutes 130 Mentoring Program 131 Honours and Awards 132 DEPARTMENT HEAD’S MESSAGE t is my pleasure to introduce the annual report of the UBC IDepartment of Medicine. 2009 was a busy and successful year despite economic challenges, and our success is a reflection of the tremendous talent and dedication of our faculty, staff, residents and students.
    [Show full text]
  • Spring 2016 Linking the BC Psychosocial Community Oncology Network
    Spring 2016 Linking the BC Psychosocial Community Oncology Network This newsletter is published by the BCCA Provincial Psychosocial Oncology Programractice for health care professionals in communities throughout British Columbia and the Yukon. What’sOnline New ? for community-based psychosocial oncology, the BC CommunityOnline Oncology Network relationship between community oncology Health Planning Day Authority social workers and the BC Cancer Agency, and regional considerations. The next step will be to In collaboration with Brenda Lynn, Provincial Director for forward these recommendations to the Agency Community Oncology Network, the BCCA Psychosocial Executive, and to continue to build on the positive Oncology Program held a planning day on February 2, momentum of the day. 2016. The purpose of the Community Oncology Network (CON) Planning Day was to bring together social workers, practice leaders and administrators across the province to map out a model for psychosocial care in community oncology and to make recommendations on how to move forward. The day included lively, interactive small and large group discussions. A professional facilitator led the group through a process of appreciative inquiry which resulted in several recommendations for the future of psychosocial care across all regions of British Columbia. Recommendations were focused on: scope of 1 BC Cancer Agency Psychosocial Oncology Program Long-Term Service Recognition 25 years 20 years 15 years Gregory Huebner Wendy MacKinnon Vickie Mattimoe Emily Oxley Elsa Borean
    [Show full text]
  • Science in the City
    Events Jobs Subscribe Contact Us Volume 2.02: January 22, 2018 ChopStitch: Exon Annotation and Splice Graph Construction Using Transcriptome Assembly and Whole Genome Sequencing Data First Author: Hamza Khan (sixth from left) | Senior Author: Inanc Birol (fourth from left) Bioinformatics | Canada's Michael Smith Genome Sciences Centre and the BC Cancer Agency The authors present ChopStitch, a new method for finding putative exons de novo and constructing splice graphs using an assembled transcriptome and whole genome shotgun sequencing (WGSS) data. ChopStitch identifies exon-exon boundaries in de novo assembled RNA-Seq data with the help of a Bloom filter that represents the k-mer spectrum of WGSS reads. Profile | Abstract Neuronal PAS Domain Protein 4 Suppression of Oxygen Sensing Optimizes Metabolism during Excitation of Neuroendocrine Cells First Author: Paul Sabatini | Senior Author: Francis Lynn (pictured) Cell Reports | BC Children's Hospital Research Institute and UBC Depolarization of neuroendocrine cells results in calcium influx, which induces vesicle exocytosis and alters gene expression. The authors hypothesized that cellular mechanisms exist to maximize energy production during excitation, and demonstrated that NPAS4, an immediate early basic helix-loop-helix-PAS transcription factor, acts to maximize energy production by suppressing hypoxia- inducible factor 1α. Abstract A Library-Based Screening Method Identifies Neoantigen-Reactive T Cells in Peripheral Blood Prior to Relapse of Ovarian Cancer First Author: Spencer Martin | Senior Author: Brad Nelson (pictured) OncoImmunology | BC Cancer Agency, UBC, and SFU While there are anecdotal reports of neoantigen-specific T cells being present in the peripheral blood and/or tumors of cancer patients, effective adoptive cell therapy against neoantigens will require reliable methods to isolate and expand rare, neoantigen-specific T cells from clinically available biospecimens, ideally prior to clinical relapse.
    [Show full text]
  • Gavin Ha Research Summary Faculty Positions Research Experience Education Honors and Awards
    GAVIN HA Fred Hutchinson Cancer Research Center 1100 Fairview Ave. N. Seattle, WA 98109 Tel: 206-667-2802 [email protected] GavinHaLab.org RESEARCH SUMMARY My laboratory is interested in studying the role of genomic alterations in cancer and expanding applications for precision medicine. We develop novel algorithms to identify genomic structural alterations in tumor and circulating cell-free DNA from patients with cancer. Our goals are to uncover the genetic and epigenetic mechanisms of treatment resistance, to identify blood-based genomic biomarkers, and to translate these findings and innovations to advance clinical research and precision medicine. FACULTY POSITIONS 2018 – Assistant Member, Computational Biology Program, Public Health Sciences Division Fred Hutchinson Cancer Research Center, Seattle, WA 2019 – Affiliate Assistant Professor, Department of Genome Sciences University of Washington, Seattle, WA RESEARCH EXPERIENCE 2014 – 2018 Postdoctoral Research Fellow, Dana-Farber Cancer Institute, Boston, MA and Broad Institute of Harvard and MIT, Cambridge, MA Mentor: Dr. Matthew Meyerson 2009 – 2014 Graduate Student, BC Cancer Agency, University of British Columbia, Canada Advisors: Drs. Sohrab P. Shah and Samuel Aparicio EDUCATION 2008 – 2014 Ph.D., Bioinformatics University of British Columbia, Vancouver, BC, Canada 2003 – 2008 B.Sc., Computer Science & Microbiology/Immunology University of British Columbia, Vancouver, BC, Canada HONORS AND AWARDS 2019 – Prostate Cancer Foundation Young Investigator Award 2019 – NIH NCI Transition
    [Show full text]
  • Cancer Incidence and Adverse Pregnancy Outcome in Registered Nurses Potentially Exposed to Antineoplastic Drugs
    Ratner et al. BMC Nursing 2010, 9:15 http://www.biomedcentral.com/1472-6955/9/15 RESEARCH ARTICLE Open Access Cancer incidence and adverse pregnancy outcome in registered nurses potentially exposed to antineoplastic drugs Pamela A Ratner1*, John J Spinelli2, Kris Beking3, Maria Lorenzi2, Yat Chow4, Kay Teschke5, Nhu D Le2, Richard P Gallagher2, Helen Dimich-Ward3 Abstract Background: To determine the relationships of potential occupational exposure to antineoplastic drugs with cancer incidence and adverse pregnancy outcomes in a historical prospective cohort study of female registered nurses (RNs) from British Columbia, Canada (BC). Methods: Female RNs registered with a professional regulatory body for at least one year between 1974 and 2000 formed the cohort (n = 56,213). The identifier file was linked to Canadian cancer registries. An RN offspring cohort from 1986 was created by linkages with the BC Birth and Health Status Registries. Exposure was assessed by work history in oncology or cancer agencies (method 1) and by estimating weighted duration of exposure developed from a survey of pharmacists and nursing unit administrators of all provincial hospitals and treatment centers and the work history of the nurses (method 2). Relative risks (RR) were calculated using Poisson regression for cancer incidence and odds ratios (OR) were calculated for congenital anomaly, stillbirth, low birth weight, and prematurity incidence, with 95% confidence intervals. Results: In comparison with other female RNs, method 1 revealed that RNs who ever worked in a cancer center or in an oncology nursing unit had an increased risk of breast cancer (RR = 1.83; 95% CI = 1.03 - 3.23, 12 cases) and their offspring were at risk for congenital anomalies of the eye (OR = 3.46, 95% CI = 1.08 - 11.14, 3 cases).
    [Show full text]
  • First Nations Cancer Survivorship Care Plan
    First Nations Cancer Survivorship Care Plan First Nations Cancer Survivorship Care Plan This plan is prepared for: [Patient name] on: [Today’s date] by: [Name of overseeing HCP] [Contact information] Acknowledgments: This care plan was created for First Nation cancer survivors living in rural and remote communities in northern British Columbia. The purpose of this care plan is to provide information to survivors and improve communication between health care professionals and patients. This care plan does not substitute health care services or advice provided by professionals. Thank you to the survivors, health care professionals and expert key informants whose insight and knowledge made the development and validation of this care plan possible. Your expertise has helped to address unmet needs in your communities and the stories you have shared have been very empowering. Production of this care plan has been made possible through funding from the Public Health Agency of Canada. We would like to thank the following community research assistants for their contribution to this project. Terri Stewart Karon McKay Bill Blackwater Stacey Pierre Margo French Editors Rob Olson, MD, FRCPC, MSc Pam Tobin, MA Care Plan Development Team Kristin Turnbull, BHSc Dana Munroe, BSc Chelan Zirul, MA Rehana Manji, BSc Amanda Ward, PhD Expert Key Informants Frankie Goodwin, RN, BN; Gina McKenzie, MSW; Howard Lim, MD, PhD, FRCPC; Janine Giese-Davis, PhD; Jeff Sisler, MD, MCISc, FCFP; Jill Taylor-Brown, MSW, RSW; Kerry Courneya, PhD; Lois Smith, BSW, RSW, MEd; Lorna Weir, MD, FRCPC; Lorraine Thibeault, MA; Maureen Parkinson, CCRC, MEd; Robb Watt, BSc (Pharm); Scott Tyldesley, MD, FRCPC.
    [Show full text]
  • Canadian Team Develops Method for Hospitals to Make Critical Medical Isotope Without Reactors Team Makes Technetium Isotopes on Existing Cyclotrons in Ontario, BC
    Canada’s national laboratory for particle and nuclear physics Laboratoire national canadien pour la recherche en physique nucléaire et en physique des particules News Release | For Immediate Release | February 20, 2012, 8:00 a.m. PST Canadian team develops method for hospitals to make critical medical isotope without reactors Team makes technetium isotopes on existing cyclotrons in Ontario, BC (Vancouver, BC) --- At a special session at the annual meeting of the American Association for the Advancement of Science, a team led by TRIUMF announced the successful production of the key medical isotope technetium-99m on cyclotrons already available in Ontario and British Columbia. This development allows hospitals and clinics with existing cyclotrons to make the isotope traditionally only available from nuclear reactors. The team includes TRIUMF, BC Cancer Agency, Lawson Health Research Institute, and the Centre for Probe Development and Commercialization. Paul Schaffer, head of TRIUMF’s Nuclear Medicine Division and one of the team leaders, said, “Making medical isotopes in hospitals instead of nuclear reactors is a major milestone for diagnostic imaging for patients in Canada and around the world. We took the principles of physics, chemistry, and engineering that people have known for years, and used them to write a recipe for upgrading a cyclotron so it could be used to make technetium-99m. We’ve just completed using that recipe on machines in both Ontario and BC.” Each year, tens of millions of medical procedures are conducted around the world with technetium-99m, an isotope used in radiopharmaceuticals for imaging disease in the heart, bones, and elsewhere in the body.
    [Show full text]